Table 2.

Overview of administered activities, time to SCT and achieved/estimated organ and myeloma doses

Patient	Day	Activity	Limit	Nuclide	SCT		Liver	Spleen	Marrow	Kidneys	Tumor	PFS8	OS9
	1	GBq 2	GBq 3		No.4	Day 5	Gy/GBq6	Gy/GBq6	Gy/GBq7	Gy/GBq7	Gy/GBq7	Days	Days10
#1	0	0.24		177Lu			0.38	0.49	0.35	1.39	3.3	29	204
	6	15.2	16.5	177Lu	2	32	0.37	0.47	0.23	0.69	3.5	41
	73	4.6		90Y	3	14						38
	122	4.5		90Y	4	14
#2	0	0.21		177Lu			0.62	1.70	2.43	0.63	4.9	110	115
	8	6.3	7.8	90Y	4	14
#3	0	0.20		177Lu			0.79	1.74	0.71	1.08	9.5	22	22
	8	23.5	21.3	177Lu	5	14	0.56	1.40	0.41	0.53	3.0
#4	0	0.20		177Lu			0.95	1.00	1.55	2.53	4.6	175	313
	22	7.8	9.1	177Lu	4	20	0.75	0.81	0.97	1.53	4.8
#5	0	0.21		177Lu			0.85	0.8	1.08	2.25		86	311
	7	9.9	10.2	177Lu	3	17	0.63	0.73	0.83	1.62
#6	0	0.20		177Lu			0.54	0.69	0.62	2.21	0.70	67	241
	14	7.6	10.4	177Lu	3	22	0.45	0.68	0.58	1.76	0.57
#7	0	0.21		177Lu			0.39	1.03	0.32	1.36	5.1	120	241
	14	14.6	16.9	177Lu	3	21	0.43	0.83	0.36	0.96	4.5
#8	0	0.21		177Lu			1.27	1.95	5.4	3.07	17.6	13	13
	2	2.6	2.1	90Y	2	n/a

¹⁾ Time after the pre-therapeutic dosimetry study; ²⁾ Administered activity;

³⁾ Activity limit calculated from the pre-therapeutic dosimetry to induce 23 Gy kidney dose;

⁴⁾ Total number of stem cell transplants (SCT); ⁵⁾ Time of SCT after therapy; ⁶⁾ Mean absorbed dose;

⁷⁾ Highest absorbed dose measured in in a contiguous 1 ml volume;

⁸⁾ Progression-free survival;

⁹⁾ Overall survival; ¹⁰⁾ Censoring date of data on June, 30th, 2016

Individual activities of [¹⁷⁷Lu]Pentixather administered for the pre-therapeutic dosimetry study and the measured specific absorbed doses in the kidneys, liver spleen, bone marrow, and tumor are listed for each patients.

If available, the specific absorbed doses measured after treatment with [¹⁷⁷Lu]Pentixather are also shown. For the pure ß-emitter ⁹⁰Y, only estimates for absorbed myeloma doses were derived from pre-therapeutic dosimetry.